Holen Sie sich die Stockscreener-App
38.59
2.62%
-1.04
Vorhandelsmarkt:
37.78
-0.81
-2.10%
Überblick
Nachrichten
Preisverlauf
Optionskette
Warum fällt NVO?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$39.63
Offen:
$38.5
24-Stunden-Volumen:
43.79M
Relative Volume:
1.98
Marktkapitalisierung:
$171.60B
Einnahmen:
$46.77B
Nettoeinkommen (Verlust:
$15.45B
KGV:
11.13
EPS:
3.468
Netto-Cashflow:
$4.40B
1W Leistung:
-21.84%
1M Leistung:
-38.02%
6M Leistung:
-32.27%
1J Leistung:
-57.40%
1-Tages-Spanne:
$38.36
$39.07
1-Wochen-Bereich:
$38.36
$49.35
52-Wochen-Spanne:
$38.36
$93.80
Novo Nordisk Adr Stock (NVO) Company Profile
Compare NVO vs LLY, JNJ, ABBV, AZN, NVS
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NVO
Novo Nordisk Adr
|
38.59 | 176.22B | 46.77B | 15.45B | 4.40B | 3.468 |
|
LLY
Lilly Eli Co
|
1,042.15 | 998.60B | 65.18B | 20.64B | 5.96B | 22.59 |
|
JNJ
Johnson Johnson
|
246.28 | 592.45B | 94.19B | 26.80B | 19.70B | 11.05 |
|
ABBV
Abbvie Inc
|
228.44 | 405.58B | 61.16B | 4.19B | 17.82B | 2.3614 |
|
AZN
Astrazeneca Plc
|
206.61 | 317.72B | 58.80B | 10.24B | 8.98B | 3.2788 |
|
NVS
Novartis Ag Adr
|
167.11 | 314.27B | 54.72B | 14.02B | 15.32B | 7.1855 |
Novo Nordisk Adr Stock (NVO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-12 | Hochstufung | Jefferies | Underperform → Hold |
| 2026-01-27 | Eingeleitet | Citigroup | Neutral |
| 2025-12-08 | Herabstufung | Argus | Buy → Hold |
| 2025-10-27 | Fortgesetzt | Jefferies | Underperform |
| 2025-10-01 | Hochstufung | HSBC Securities | Hold → Buy |
| 2025-09-29 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2025-09-17 | Hochstufung | Berenberg | Hold → Buy |
| 2025-09-16 | Hochstufung | Rothschild & Co Redburn | Neutral → Buy |
| 2025-09-09 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2025-08-13 | Hochstufung | BNP Paribas Exane | Underperform → Neutral |
| 2025-08-05 | Herabstufung | UBS | Buy → Neutral |
| 2025-07-31 | Herabstufung | HSBC Securities | Buy → Hold |
| 2025-07-30 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2025-04-17 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2025-03-13 | Hochstufung | Kepler | Hold → Buy |
| 2025-03-03 | Herabstufung | Stifel | Buy → Hold |
| 2025-02-12 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2025-01-06 | Hochstufung | Bernstein | Underperform → Mkt Perform |
| 2024-05-30 | Eingeleitet | Goldman | Buy |
| 2024-04-12 | Eingeleitet | BMO Capital Markets | Outperform |
| 2024-01-23 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-01-16 | Fortgesetzt | UBS | Neutral |
| 2023-12-01 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-10-02 | Eingeleitet | Argus | Buy |
| 2023-07-14 | Eingeleitet | HSBC Securities | Buy |
| 2022-07-15 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2022-06-28 | Herabstufung | UBS | Neutral → Sell |
| 2022-06-27 | Hochstufung | Exane BNP Paribas | Underperform → Neutral |
| 2022-06-07 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2022-05-31 | Hochstufung | Guggenheim | Neutral → Buy |
| 2022-04-25 | Hochstufung | Cowen | Market Perform → Outperform |
| 2022-04-12 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2022-03-16 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2022-01-25 | Herabstufung | Liberum | Hold → Sell |
| 2021-12-20 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2021-12-17 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2021-01-20 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2021-01-15 | Eingeleitet | Deutsche Bank | Buy |
| 2020-09-29 | Eingeleitet | Berenberg | Hold |
| 2020-07-06 | Herabstufung | BofA Securities | Buy → Neutral |
| 2020-05-11 | Herabstufung | UBS | Buy → Neutral |
| 2020-05-04 | Eingeleitet | Cowen | Market Perform |
| 2020-03-16 | Hochstufung | BofA/Merrill | Neutral → Buy |
| 2020-01-03 | Herabstufung | Guggenheim | Buy → Neutral |
| 2019-11-18 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2019-09-17 | Hochstufung | Citigroup | Neutral → Buy |
| 2019-08-30 | Herabstufung | Jefferies | Hold → Underperform |
| 2019-06-20 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2019-06-11 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2019-04-29 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2019-01-29 | Eingeleitet | Exane BNP Paribas | Outperform |
| 2018-12-11 | Fortgesetzt | Jefferies | Hold |
| 2018-10-09 | Eingeleitet | Guggenheim | Buy |
| 2017-12-29 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2017-12-06 | Hochstufung | BofA/Merrill | Neutral → Buy |
| 2017-12-01 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2017-09-25 | Herabstufung | Exane BNP Paribas | Outperform → Neutral |
| 2017-09-06 | Hochstufung | BofA/Merrill | Underperform → Neutral |
Alle ansehen
Novo Nordisk Adr Aktie (NVO) Neueste Nachrichten
Could Novo Nordisk Help Turn $100,000 Into $1 Million in the GLP‑1 Gold Rush? - The Motley Fool
Novo Nordisk Is Losing Share, but We Still See Its Portfolio and Pipeline Supporting a Wide Moat - Morningstar
Stock Of The Day: Breakdown In Novo Nordisk? - Finviz
Why did NVO stock crash over 14% today? Novo Nordisk’s weight-loss drug CagriSema misses trial goal agains - The Economic Times
Pre-market Overview | Uncertainty looms over US tariff policy! All three major futures indices trend lower; popular Chinese ADRs active in pre-market trading, with PDD Holdings up over 3%; Novo-Nordisk A/S plunges 14% as its next-generation weight-loss dr - 富途牛牛
Novo Nordisk sinks 16% after weight loss drug fails to match Eli Lilly's in trial - CNBC
Does Novo Nordisk A s (b Shares) Adrhedged stock benefit from AI growthQuarterly Profit Review & AI Powered Buy/Sell Recommendations - mfd.ru
Novo Nordisk stock forecast: Analysts mixed on Q4 earnings & 2026 guidance - Capital.com
Glucagon-like Peptide 1 (GLP-1) Market Report 2026-2035: Market to Reach $33.26 Billion by 2030 - GlobeNewswire Inc.
EU Approves Novo Nordisk's Higher-Dose Wegovy for Obesity Patients - Finviz
Alzheimer's Therapeutics Market Research Report 2026-2036: Growing Global Burden of Alzheimer's Continues to Drive Demand - GlobeNewswire Inc.
Novo Nordisk Balances Oral Wegovy Launch With Legal Fight On Compounds - Sahm
Novo Nordisk Faces Legal And FDA Challenges As Valuation Gap Widens - Sahm
FDA Crackdown Reshapes Wegovy Competition And Risks For Novo Nordisk Investors - Sahm
Can Novo Nordisk A s (b Shares) Adrhedged outperform in the next rallyIPO Watch & Safe Capital Growth Stock Tips - mfd.ru
Where is Novo Nordisk A/S (NVO) Headed? - Finviz
Novo Nordisk Lawsuit Tests Obesity Drug Patents And Valuation Upside - Sahm
Novo Nordisk A/S (NVO) Eyes Solidifying Its Market Position with Increased Advertising Spending - Finviz
Jim Cramer on Novo Nordisk: "It Seems Eli Lilly's Eating Their Lunch" - Finviz
Novo Nordisk Warning Tests Valuation As Pricing And Competition Intensify - Sahm
Ozempic Maker Novo Nordisk Flags Declining Sales In 2026 - Sahm
Novo Nordisk Faces a Sales Decline in 2026, But Its Portfolio and Pipeline Provide Long-Term Growth - Morningstar
Novo Nordisk Plunges After Releasing a Brutal Forecast. Should You Dump the Stock? - Finviz
NVO Q4 Earnings & Sales Beat Estimates, Stock Down on Poor 2026 View - Finviz
Finanzdaten der Novo Nordisk Adr-Aktie (NVO)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.46%
0.30%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):